Actualising the power of antibody-drug conjugates as cancer therapeutics
European Pharmaceutical Review
AUGUST 24, 2022
tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs. He also co-founded ChromoTek GmbH, a company focused on developing nanobody derivatives for proteome analysis and cell-based diagnostics. Tubulis’ second technology platform is called Tub?tag References.
93 
Let's personalize your content